April 10, 2019 – Tuberculosis (TB) is the number-one killer of people living with HIV. Using TB lipoarabinomannan (LAM) tests, an inexpensive, urine-based test, has been proven to decrease mortality rates and allow for earlier diagnosis among people living with…
TAG’s executive director Mark Harrington spoke at the U.S. Senate briefing held on March 28, 2019, not long after World TB Day. He invoked the stories of leaders that had tuberculosis, such as Eleanor Roosevelt and Nelson Mandela, on the…
Treatment Action Group (TAG) opposes the President's FY 2020 budget proposal, which makes a mockery of the administration's purported strategy to end AIDS in the United States over the next decade.
Treatment Action Group (TAG) welcomes the exciting news of a novel tuberculosis (TB) drug entering priority review by the Food and Drug Administration (FDA). Pretomanid represents only the fourth new TB drug to go through stringent regulatory review in the past half a century, and the first developed by a not-for-profit organization.
In our two briefs, Closing the Gap in Tuberculosis Research and Development Funding: Actions for U.S. Government Executive Agencies and Actions for U.S. Congress, we detail how a funding increase of 0.1 percent, based on "fair share" of research capacity, would close the funding gap in TB R&D, catalyze new public health tools we need to create positive health outcomes among communities vulnerable to TB worldwide.
TAG recently submitted a public comment to the National Institute on Drug Abuse (NIDA) at the National Institute of Health to inform a strategic plan it is developing to support research at the intersection of HIV and drug use.
Good COPs or Bad COPs 2.0: Advocacy to Ensure the Prioritization of TB in 2019 PEPFAR Country Operational Plans (COPs) Every year, PEPFAR meets to discuss their strategy and budget for the following year, and set targets on implementing country operation plans…
TAG recently submitted this public comment on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions, highlighting the need to mitigate national supply challenges and shortages of critical TB drugs.
On January 11, 2019, TB Project Co-Director Lindsay McKenna attended a half-day conference hosted by the NYC Bureau of Tuberculosis Control. The recommendations from the conference are included in the NYC Department of Health and Mental Hygiene’s press release on the event, which you can download below.
by Mike Frick and Lindsay McKenna, TB Project Co-Directors, TAG In an interview with TAG’s Tuberculosis (TB) Project, Marc Destito, Senior Director of Public Affairs and Global Alliance Management at Otsuka Pharmaceutical, provides insight into how the development of TB…